Prostate cancer kills: Strategy to reduce deaths
UrologyPublished 1 October 1994
Patrick C. Walsh
Citations60
SJR quartileQ2
SJR score0.76
SNIP0.84
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
It is shown that prostate this year, that it is the eath in men, and that • are increasing every fewer men are dying this message is rarely ;.
Abstract
s know that prostate this year, that it is the eath in men, and that • are increasing every fewer men are dying this message is rarely ;. Instead, patients are ostate cancer at some J few people die of it. 1 ?f this has been a mis.courage early diagnoreason, I have put tomuses on death from can say anything they Lave the responsibility :e for pa t i en t s w i th . that it is our respon:hs from prostate canwill? Let us review a
Keywords
Medicine
JAMAPathologic and Clinical Findings to Predict Tumor Extent of Nonpalpable (Stage T1 c) Prostate Cancer
1,797 Citations1994Jonathan I. Epstein
Serum PSA level, PSA density, and needle biopsy pathologic findings are accurate predictors of tumor extent and it may be reasonable to follow up some patients whose tumors are most likely insignificant with serial PSA measurements and repeated biopsies.
New England Journal of MedicineResults of Conservative Management of Clinically Localized Prostate Cancer
955 Citations1994Gerald W. Chodak, Ronald A. Thisted +8 more
The strategy of initial conservative management and delayed hormone therapy is a reasonable choice for some men with grade 1 or 2 clinically localized prostate cancer, particularly for those who have an average life expectancy of 10 years or less.
CancerGeographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation
655 Citations1992Carol Hanchette, Gary G. Schwartz
It was hypothesized that low levels of vitamin D, a hormone with potent antitumor properties, may increase the risk for clinical prostate cancer.
The Journal of UrologyHereditary Prostate Cancer: Epidemiologic and Clinical Features
614 Citations1993Bob S. Carter, G. Steven Bova +5 more
JAMAA Decision Analysis of Alternative Treatment Strategies for Clinically Localized Prostate Cancer
556 Citations1993Craig Fleming
PubMedSerum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.
555 Citations1993Alan W. Partin, Charles R. Pound +3 more
The long-term value of serum PSA as a measure of progression after anatomic radical prostatectomy is demonstrated and suggests that radiation therapy is not effective in sterilizing occult local residual tumor in many men.
Annals of Internal MedicineRisk Factors for Prostate Cancer
488 Citations1993Kenneth J. Pienta, Peggy S. Esper
The data suggest that the initiation rate of prostate cancer may be the same in both groups but that there appear to be differences in the rate of promotion or progression to clinically evident prostate cancer.
Urologic Clinics of North AmericaSERUM PSA AFTER ANATOMIC RADICAL PROSTATECTOMY
472 Citations1993Alan W. Partin, Charles R. Pound +3 more
JAMAHigh 10-Year Survival Rate in Patients With Early, Untreated Prostatic Cancer
467 Citations1992Jan‐Erik Johansson
The low disease-specific mortality rate, especially in patients with highly and moderately differentiated tumors, means that any local or systemic therapy intended for patients with early prostatic cancer must be evaluated in clinical trials with untreated controls for comparison.
International Journal of Radiation Oncology*Biology*PhysicsThe effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 1251 implantation
451 Citations1991Zvi Fuks, Steven A. Leibel +6 more
The existence and re-growth of local residual disease in localized prostatic carcinoma promotes an enhanced spread of metastatic disease, and that early and complete eradication of the primary tumor is required if a long term cure is to be achieved, although the clinical expression of secondary metastases may not become apparent for 6.5 years or more in one-half of the patients.
JAMAPathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
386 Citations1994Jonathan I. Epstein
The Journal of UrologyLong-term Survival and Mortality in Prostate Cancer Treated with Noncurative Intent
193 Citations1995Gunnar Aus, Jonas Hugosson +1 more
Mortality in patients with stage M0 prostate cancer was surprisingly high when followup exceeded 10 years, and among the 65 patients who survived at least 10 years the mortality rate due to prostatecancer was 63%.
JAMAA decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team
135 Citations1993C. Fleming
Radical prostatectomy and radiation therapy may benefit selected groups of patients with localized prostate cancer, particularly younger patients with higher-grade tumors, and watchful waiting is a reasonable alternative to invasive treatment for many men with localized prostatic carcinoma.
British Journal of UrologyDeferred Treatment in Clinically Localised Prostatic Carcinoma
113 Citations1992Jan Adolfsson, John Carstensen +1 more
A series of 122 patients with a cytological diagnosis of well or moderately differentiated and clinically localised (T1-2) prostatic carcinoma were followed up without any initial anti-tumour therapy and 47 patients died, 38 of them from prostatic cancer.
EndocrinologyEffect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5 alpha-reductase inhibitor, on the prostate and testes of beagle dogs.
27 Citations1993Paul E. Juniewicz, Susan Hoekstra +7 more
Combination therapy using zanoterone and finasteride for the treatment of human androgen-dependent disorders such as benign prostatic hyperplasia and prostate cancer has potential utility.
